Trials
596 randomized trials, each extracted independently by two reviewers and every disagreement adjudicated. Only aggregate data printed in the trial reports and registries are shown.
596 of 596 trials
| Trial | Treatments | Start | Randomized | Weeks |
|---|---|---|---|---|
| S003109 | Standard care or no added treatment, Liraglutide 1.2 mg subcutaneous once daily | 39 | 12 | |
| S003105 | Liraglutide 1.8 mg subcutaneous once daily, Placebo | 18 | 3 | |
| S003055 | liraglutide and dapagliflozin, Vildagliptin glimepiride | 29 | 12 | |
| S003098 | exenatide, Placebo | 8 | 0.02 | |
| S003091 | Insulin, Liraglutide 1.2 mg subcutaneous once daily, Standard care or no added treatment | 120 | ||
| S003090 | Standard care or no added treatment, Dulaglutide 0.75 mg subcutaneous once weekly | 1 | ||
| S003087 | Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability, Standard care or no added treatment | 65 | 2 | |
| S003032 | Standard care or no added treatment, Semaglutide 1.0 mg subcutaneous once weekly | 50 | 34.76 | |
| S003425 | Standard care or no added treatment, Dapagliflozin, Liraglutide 1.8 mg subcutaneous once daily | 115 | 13.04 | |
| S003440 | dulaglutide, Metformin | 200 | 26.07 | |
| S003034 | Liraglutide 1.8 mg subcutaneous once daily, Colesevelam | 52 | 6 | |
| S002930 | Semaglutide 1.0 mg subcutaneous once weekly, Sitagliptin | 34 | 52 | |
| S003035 | Liraglutide 1.2 mg subcutaneous once daily, Insulin glargine | 13 | 12 | |
| S002879 | Dulaglutide 0.75 mg subcutaneous once weekly, Standard care or no added treatment | 30 | 52.14 | |
| NCT00064714 Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes | exenatide, Standard care or no added treatment | 16 | 52.14 | |
| S002949 | liraglutide or dulaglutide (continued), semaglutide | 24 | ||
| S003172 | exenatide, Placebo, Moxifloxacin | 86 | 0.4 | |
| S003441 | Dulaglutide 1.5 mg subcutaneous once weekly, Metformin | 52.18 | ||
| S003431 | Lifestyle intervention (randomized arm), liraglutide or semaglutide | 60 | 24 | |
| S003151 | Placebo, exenatide | 24 | ||
| S002858 | Lixisenatide 20 ug subcutaneous once daily, Placebo | 101 | 24 | |
| S003148 | GLP-1 receptor agonist (liraglutide or lixisenatide), Standard care or no added treatment | 559 | 52.14 | |
| S003146 | Placebo, exenatide | 10 | 0.02 | |
| S002992 | IGlarLixi 2:1 pen subcutaneous once daily titrated, Premixed insulin | 887 | 26 | |
| S003430 | Liraglutide 3.0 mg subcutaneous once daily, Placebo | 120 | 6 | |
| S003138 | Placebo, GLP-1-gFc | 48 | ||
| S003052 | liraglutide, Sitagliptin, Lifestyle intervention (randomized arm) | 88 | 14 | |
| S003132 | Empagliflozin, Liraglutide 1.8 mg subcutaneous once daily | 120 | 24 | |
| S003110 | Intensive insulin, exenatide | 24 | ||
| S003107 | liraglutide, Vildagliptin, Alogliptin | 10 | ||
| S002961 | liraglutide | 37 | ||
| S003082 | Exenatide 10 ug subcutaneous twice daily, Metformin | 82 | 12 | |
| S003077 | liraglutide (NN2211), Placebo | 30 | 1.43 | |
| S003074 | exenatide, Placebo | 20 | ||
| S003070 | Standard care or no added treatment, Liraglutide 1.8 mg subcutaneous once daily | 60 | 2 | |
| S002995 | liraglutide, Standard care or no added treatment | 24 | 12 | |
| S003068 | Liraglutide 0.9 mg injection once daily, Standard care or no added treatment | 19 | 36 | |
| S003058 | Lixisenatide 20 ug subcutaneous once daily, Vildagliptin | 48 | 12 | |
| S003060 | Placebo, lixisenatide | 22 | 0.14 | |
| S002974 | insulin glargine and lixisenatide (iGlarLixi) | 20 | ||
| S002993 | semaglutide | 314 | 24 | |
| S003008 | exenatide extended release, Standard care or no added treatment | 28 | 24 | |
| S002963 | Liraglutide 3.0 mg subcutaneous once daily, Placebo | 6 | ||
| S003428 | Liraglutide 0.6 mg subcutaneous once daily, Liraglutide 1.2 mg subcutaneous once daily, Liraglutide 1.8 mg subcutaneous once daily | 60 | 26.07 | |
| S003023 | Liraglutide 1.2 mg injection, Standard care or no added treatment | 0.43 | ||
| S003014 | Standard care or no added treatment, Dapagliflozin, Liraglutide 1.8 mg subcutaneous once daily | 115 | 26.07 | |
| S003002 | Semaglutide 2.0 mg subcutaneous once weekly, Placebo | 31 | 36 | |
| S003426 | Semaglutide 0.5 mg subcutaneous once weekly, Tirzepatide 5 mg subcutaneous once weekly | 79 | 24 | |
| S003012 | semaglutide | 2025 | 223 | 24 |
| S003437 | Metformin, Semaglutide 1.0 mg subcutaneous once weekly, Semaglutide 2.4 mg subcutaneous once weekly | 2025 | 180 | 24 |
| NCT06896981 Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial | Metformin, Semaglutide 0.5 mg subcutaneous once weekly | 2025 | 31 | 16 |
| GALLOP2 Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment | Semaglutide 0.5 mg subcutaneous once weekly, Standard care or no added treatment | 2025 | 390 | 1 |
| FALCON A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity | Placebo, TERN-601 250 mg tablet once daily, TERN-601, TERN-601 750 mg tablet once daily | 2025 | 167 | 12 |
| S002985 | Semaglutide 2.4 mg subcutaneous once weekly | 2025 | 267 | 24 |
| S003130 | Standard care or no added treatment, Insulin, GLP-1 receptor agonist (agent not reported) | 2024 | 199 | 12 |
| S003439 | semaglutide | 2024 | 60 | 0.14 |
| NCT07370922 Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia | Dulaglutide 0.75 mg subcutaneous once weekly, Basal bolus insulin | 2024 | 80 | 24 |
| S003153 | liraglutide and dapagliflozin, Dapagliflozin, Liraglutide 1.8 mg subcutaneous once daily | 2024 | 360 | 24 |
| S003007 | Tirzepatide 5 mg subcutaneous once weekly, Placebo | 2024 | 24 | 12 |
| ACCESS A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity | Aleniglipron 45 mg tablet once daily, Aleniglipron 90 mg tablet once daily, Aleniglipron 120 mg tablet once daily, Placebo | 2024 | 230 | 36 |
| NCT06584916 A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | orforglipron, Placebo | 2024 | 376 | 52 |
| TOGETHER-PsA Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA) | Standard care or no added treatment, Tirzepatide maximum tolerated dose injection once weekly | 2024 | 279 | 52 |
| OUTSTAND-1 A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise (OUTSTAND-1) | Safiglipron (HRS-7535) 30 mg tablet once daily, Safiglipron (HRS-7535) 60 mg tablet once daily, Safiglipron (HRS-7535) 90 mg tablet once daily, Placebo | 2024 | 284 | 52 |
| NCT06250946 A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects | Placebo, HRS-7535 30 mg tablet once daily, HRS-7535 60 mg tablet once daily, HRS-7535 120 mg tablet once daily, HRS-7535 180 mg tablet once daily | 2024 | 235 | 36 |
| S002920 | Insulin glargine, Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | 2024 | 126 | 1 |
| SOLID-DKD A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes | HRS-7535 30 mg tablet once daily, HRS-7535 90 mg tablet once daily, Placebo | 2024 | 281 | 16 |
| S003046 | PG-102, Placebo | 2024 | 24 | 5 |
| NCT06440980 A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy. | orforglipron, Orforglipron 36 mg oral once daily, Orforglipron 3 mg oral once daily, Orforglipron 6 mg oral once daily, Orforglipron 12 mg oral once daily, Orforglipron 24 mg oral once daily | 2024 | 429 | 15 |
| TOGETHER-PsO Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO) | Standard care or no added treatment, Tirzepatide maximum tolerated dose injection once weekly | 2024 | 281 | 52 |
| NCT06589765 A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2) | Safiglipron (HRS-7535) 30 mg tablet once daily, Safiglipron (HRS-7535) 60 mg tablet once daily, Safiglipron (HRS-7535) 90 mg tablet once daily, Dapagliflozin | 2024 | 810 | 52 |
| NCT06309992 Multicentre, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH) | Survodutide 6.0 mg subcutaneous once weekly, Placebo | 2024 | 218 | 48 |
| ACHIEVE-1 A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Placebo, Orforglipron 3 mg oral once daily, Orforglipron 12 mg oral once daily, Orforglipron 36 mg oral once daily | 2023 | 559 | 40 |
| S003009 | Polyethylene glycol loxenatide 0.2 mg subcutaneous once weekly, Dapagliflozin | 2023 | 88 | 24 |
| ATTAIN-2 A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) | Placebo, Orforglipron 6 mg oral once daily, Orforglipron 12 mg oral once daily, Orforglipron 36 mg oral once daily | 2023 | 1,613 | 72 |
| S002991 | Semaglutide flexible dose injection once weekly, Insulin aspart (prandial) | 2023 | 220 | 13.04 |
| S003436 | Metformin, Liraglutide 0.9 mg injection once daily | 2023 | 150 | 24 |
| VENTURE A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition | Placebo, VK2735 2.5 mg injection once weekly, VK2735 5.0 mg injection once weekly, VK2735 10 mg injection once weekly, VK2735 15 mg injection once weekly | 2023 | 176 | 13 |
| NCT06827002 Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults | Placebo, Dichrostachys glomerata extract, Cissus quadrangularis extract, Semaglutide 14 mg oral once daily (original tablet) | 2023 | 248 | 16 |
| NCT06974825 A Randomized, Double-blind, Placebo and Positive Drug Parallel-controlled Phase IIa Clinical Study Protocol to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple-dose BGM0504 Injection in Patients With Type 2 Diabetes Mellitus | BGM0504 5 mg injection once weekly, BGM0504 10 mg injection once weekly, BGM0504 15 mg injection once weekly, Semaglutide 1.0 mg subcutaneous once weekly, Placebo | 2023 | 67 | 18 |
| DREAM Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial | Placebo, Dapiglutide 4 mg injection once weekly, Dapiglutide 6 mg injection once weekly | 2023 | 54 | 12 |
| SEMA-VR Semaglutide and Vascular Regeneration in People With Diabetes and/or Obesity | Standard care or no added treatment, Semaglutide 1.0 mg subcutaneous once weekly | 2023 | 73 | 26.07 |
| GALLOP Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies - a Pilot Study | Semaglutide 0.5 mg subcutaneous once weekly, Standard care or no added treatment | 2023 | 140 | 1 |
| S003422 | Standard care or no added treatment, Semaglutide 1.0 mg subcutaneous once weekly | 2023 | 64 | 12 |
| NCT05990374 Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Ebenatide 2 mg injection once weekly, Placebo | 2023 | 78 | 52 |
| NCT05786521 The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance | Semaglutide 1.0 mg subcutaneous once weekly, Standard care or no added treatment | 2023 | 20 | 20 |
| ADJUST-T1D Efficacy and Safety of Once Weekly Semaglutide in Adults With Obesity and Inadequately Controlled Type 1 Diabetes Using Hybrid Closed-Loop System. | Semaglutide 1.0 mg subcutaneous once weekly, Placebo | 2023 | 72 | 26 |
| ACHIEVE-5 A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Placebo, Orforglipron 3 mg oral once daily, Orforglipron 12 mg oral once daily, Orforglipron 36 mg oral once daily | 2023 | 546 | 40 |
| NCT06569355 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/Obese Subjects | VCT220 80 mg tablet once daily, VCT220 120 mg tablet once daily, VCT220, Placebo | 2023 | 250 | 16 |
| ATTAIN-1 A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) | Placebo, Orforglipron 6 mg oral once daily, Orforglipron 12 mg oral once daily, Orforglipron 36 mg oral once daily | 2023 | 3,127 | 72 |
| NCT06256562 A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients | Bofanglutide 12 mg injection every 2 weeks, Bofanglutide 18 mg injection every 2 weeks, Bofanglutide 24 mg injection every 2 weeks, Bofanglutide 48 mg injection every 2 weeks, Bofanglutide 24 mg injection once weekly, Placebo | 2023 | 340 | 30 |
| NCT06475586 Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus | Semaglutide 1.0 mg subcutaneous once weekly, Standard care or no added treatment | 2023 | 31 | 12 |
| ACHIEVE-3 A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3) | Orforglipron 12 mg oral once daily, Orforglipron 36 mg oral once daily, Semaglutide 7 mg oral once daily (original tablet), Semaglutide 14 mg oral once daily (original tablet) | 2023 | 1,698 | 52 |
| NCT05759897 A 16-week Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin | Placebo, Safiglipron (HRS-7535) 15 mg tablet once daily, Safiglipron (HRS-7535) 30 mg tablet once daily, Safiglipron (HRS-7535) 60 mg tablet once daily, Safiglipron (HRS-7535) 90 mg tablet once daily | 2023 | 194 | 16 |
| SURMOUNT-5 A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities | Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg, Semaglutide maximum tolerated dose injection once weekly | 2023 | 751 | 72 |
| NCT05435677 A Study Investigating the Pharmacokinetic Properties of a Single Dose of IcoSema Compared With Insulin Icodec and Semaglutide Given Separately in Chinese Participants With Type 2 Diabetes | insulin icodec and semaglutide (IcoSema), Insulin icodec, semaglutide | 2022 | 20 | |
| S003135 | Semaglutide 1.0 mg subcutaneous once weekly, Lifestyle intervention (randomized arm) | 2022 | 83 | 12 |
| S002928 | Placebo, Polyethylene glycol loxenatide 300 µg injection once weekly, Polyethylene glycol loxenatide 400 µg injection once weekly | 2022 | 123 | 24 |
| BARI-STEP BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery. | Placebo, Semaglutide 2.4 mg subcutaneous once weekly | 2022 | 70 | 68 |
| STABLE Wt Loss Short- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status | Semaglutide 2.4 mg subcutaneous once weekly, Placebo | 2022 | 120 | 60 |
| NCT05654831 A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus | Placebo, ECC5004 50 mg tablet once daily, ECC5004 5 mg tablet once daily, ECC5004 10 mg tablet once daily, ECC5004 30 mg tablet once daily | 2022 | 52 | 4 |